Abstract：
UNASSIGNED: Pneumococcal vaccines are effective in preventing pneumococcal diseases in adults. The evaluation of the antibodies persistence to the 23-valent pneumococcal polysaccharide vaccine (PPV23) could provide evidence on PPV23 revaccination.
UNASSIGNED: Adults aged ≥ 60 years were selected and vaccinated with PPV23 in Shanghai, and followed up for 5 years with blood samples collection of a 1-year interval. The geometric mean concentrations (GMC) of the IgG against 23 pneumococcal serotypes covered by PPV23 were detected using enzyme-linked immunosorbent assay. The antibodies to 23 pneumococcal serotypes among different groups was analyzed using statistical analysis.
UNASSIGNED: Overall, 517 participants completed all six visits over a 5-year period (2013-2018). The GMC of 23 serotypes in adults aged ≥ 60 years decreased slowly after PPV23 vaccination compared to baseline pre-vaccination (P < 0.05), except serotype 3. Additionally, the multiplicative increase in the antibody concentration after PPV23 vaccination was greater, and the antibody levels of serotypes 1 and 6B were significantly higher at visit 5 than at visit 4 (P < 0.05).
UNASSIGNED: The pneumococcal antibodies in elderly after PPV23 vaccination could sustain high levels over long-term follow-up, which suggested that the interval of revaccination with PPV23 in elderly should be at least 5 years after the first vaccination.
UNASSIGNED: Adults aged ≥ 60 years were selected and vaccinated with PPV23 in Shanghai, and followed up for 5 years with blood samples collection of a 1-year interval. The geometric mean concentrations (GMC) of the IgG against 23 pneumococcal serotypes covered by PPV23 were detected using enzyme-linked immunosorbent assay. The antibodies to 23 pneumococcal serotypes among different groups was analyzed using statistical analysis.
UNASSIGNED: Overall, 517 participants completed all six visits over a 5-year period (2013-2018). The GMC of 23 serotypes in adults aged ≥ 60 years decreased slowly after PPV23 vaccination compared to baseline pre-vaccination (P < 0.05), except serotype 3. Additionally, the multiplicative increase in the antibody concentration after PPV23 vaccination was greater, and the antibody levels of serotypes 1 and 6B were significantly higher at visit 5 than at visit 4 (P < 0.05).
UNASSIGNED: The pneumococcal antibodies in elderly after PPV23 vaccination could sustain high levels over long-term follow-up, which suggested that the interval of revaccination with PPV23 in elderly should be at least 5 years after the first vaccination.
摘要：
■肺炎球菌疫苗可有效预防成人肺炎球菌疾病。对23价肺炎球菌多糖疫苗（PPV23）的抗体持久性的评估可以提供PPV23再接种的证据。
■选择年龄≥60岁的成年人，在上海接种PPV23疫苗，并随访5年，间隔1年采集血样。使用酶联免疫吸附测定法检测IgG对PPV23覆盖的23种肺炎球菌血清型的几何平均浓度（GMC）。使用统计分析分析了不同组之间针对23种肺炎球菌血清型的抗体。
■总的来说，517名参与者在5年期间（2013-2018年）完成了所有6次访问。与接种前基线相比，接种PPV23疫苗后，≥60岁成人中23种血清型的GMC缓慢下降(P<0.05)，除了血清型3。此外,PPV23疫苗接种后抗体浓度的倍增增加更大，第5次访视时血清型1和6B的抗体水平显著高于第4次访视时(P<0.05)。
接种PPV23疫苗后的老年人肺炎球菌抗体在长期随访中可以维持高水平，这表明，老年人用PPV23再接种的间隔时间应至少为首次接种后5年。
■选择年龄≥60岁的成年人，在上海接种PPV23疫苗，并随访5年，间隔1年采集血样。使用酶联免疫吸附测定法检测IgG对PPV23覆盖的23种肺炎球菌血清型的几何平均浓度（GMC）。使用统计分析分析了不同组之间针对23种肺炎球菌血清型的抗体。
■总的来说，517名参与者在5年期间（2013-2018年）完成了所有6次访问。与接种前基线相比，接种PPV23疫苗后，≥60岁成人中23种血清型的GMC缓慢下降(P<0.05)，除了血清型3。此外,PPV23疫苗接种后抗体浓度的倍增增加更大，第5次访视时血清型1和6B的抗体水平显著高于第4次访视时(P<0.05)。
接种PPV23疫苗后的老年人肺炎球菌抗体在长期随访中可以维持高水平，这表明，老年人用PPV23再接种的间隔时间应至少为首次接种后5年。
